Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
    • Overview
    • Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • Analyst Coverage
    • Events
    • SEC Filings
    • FAQs
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
    ►
      ◄ Back
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • FAQs
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

All News | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Aug 08, 2022

TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 01, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 01, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 27, 2022

TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

Jun 01, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 01, 2022

TCR² Therapeutics to Participate in Two Upcoming Conferences in June

May 12, 2022

TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 02, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 01, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 22, 2022

TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
  • Get in Touch
  • Join Us

© 2022 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics